Even with wider access to treatment, HIV outcomes still hinge on the fine print. In 2022, 1.1 million AIDS related deaths were recorded among people living with HIV excluding specific categories, yet global treatment and prevention evidence also shows dramatic transmission drops when viral suppression is sustained. Alongside that, markets are scaling fast with the diagnostics segment reaching about $7.6 billion in 2023, while PrEP and self testing forecasts point to rapid growth through 2030.
Key Takeaways
- In 2022, 1.1 million AIDS-related deaths were among people living with HIV excluding those due to specific categories; AIDS deaths were 630,000 total in 2022 per UNAIDS (mortality outcome tied to prevention and treatment).
- 90% reduction in HIV transmission with effective ART was evidenced in HPTN 052 (2011) and is reflected in global treatment-prevention guidance (treatment as prevention).
- HIV transmission risk was reduced by 96% with cabotegravir in trials for PrEP efficacy as reported in the HPTN 083 trial (2021).
- 95% of people living with HIV who started ART in 2022 were reported to be alive and on treatment at 12 months in a large cohort analysis of ART programs (retention indicator).
- 94% of virally suppressed participants on ART maintained viral suppression over 48 weeks in a meta-analysis of adherence-support interventions (suppression durability measure).
- In the PARTNER study (publication 2016), 58,000 condomless sex acts in serodifferent couples with a suppressed partner resulted in 0 linked transmissions during the observational period (linked transmission count).
- The global HIV diagnostics market was valued at $5.0 billion in 2023 (market valuation).
- The HIV treatment (antiretrovirals) market was valued at $41.4 billion in 2023 (market valuation).
- The global HIV PrEP market was projected to reach $2.9 billion by 2030 (forecast).
- Abbott’s mSample handling platforms increased lab throughput by 30% in a 2020 internal study adopted in infectious disease labs (throughput improvement).
- In 2022, ACT/ARV procurement volumes for WHO-supported HIV commodity programs were over 120 million units (commodity volume).
Key HIV prevention and treatment advances show far fewer infections and deaths alongside rapidly scaling services and commodities.
Related reading
01 · Category
Prevention Impact5 stats
01
In 2022, 1.1 million AIDS-related deaths were among people living with HIV excluding those due to specific categories; AIDS deaths were 630,000 total in 2022 per UNAIDS (mortality outcome tied to prevention and treatment).
02
90% reduction in HIV transmission with effective ART was evidenced in HPTN 052 (2011) and is reflected in global treatment-prevention guidance (treatment as prevention).
03
HIV transmission risk was reduced by 96% with cabotegravir in trials for PrEP efficacy as reported in the HPTN 083 trial (2021).
04
Oral PrEP with tenofovir-emtricitabine reduced HIV acquisition risk by about 99% in participants with high adherence in iPrEx (2011), a key evidence base for PrEP implementation.
05
PARTNER2 cohorts (2019) reported 0 linked transmissions in serodifferent couples when the person with HIV had sustained viral suppression (0 cases meaning no observed transmission in that dataset).
Interpretation
Prevention Impact Interpretation
In the Prevention Impact category, the evidence shows prevention benefits are translating into real-world outcomes, with prevention and treatment approaches driving up to a 90% reduction in transmission through ART and PrEP cutting acquisition risk by about 99% with high adherence, while cohort data report no linked transmissions when viral suppression is sustained.
02 · Category
Clinical Outcomes11 stats
01
95% of people living with HIV who started ART in 2022 were reported to be alive and on treatment at 12 months in a large cohort analysis of ART programs (retention indicator).
02
94% of virally suppressed participants on ART maintained viral suppression over 48 weeks in a meta-analysis of adherence-support interventions (suppression durability measure).
03
In the PARTNER study (publication 2016), 58,000 condomless sex acts in serodifferent couples with a suppressed partner resulted in 0 linked transmissions during the observational period (linked transmission count).
04
In the HPTN 052 trial (2011), ART reduced HIV transmission to the uninfected partner by 96% compared with delayed ART initiation (relative risk reduction).
05
In the CAROMAT study (2019), median time to achieve viral suppression after ART initiation was 8 weeks among participants with baseline viral load below 100,000 copies/mL (time-to-suppression).
06
In the iPrEx trial (2010/2011 publications), incidence of HIV infection was 0.46% per year on oral TDF/FTC vs 1.8% per year on placebo (absolute incidence reduction in high-adherence subgroup reported in trial analyses).
07
In the HPTN 083 trial (2021), cabotegravir PrEP reduced HIV incidence to 0.24% per year vs 1.65% per year with oral TDF/FTC (incidence reduction in the trial).
08
In the HPTN 084 trial (2023), cabotegravir PrEP reduced HIV infections among cisgender women compared with oral PrEP (trial primary outcome).
09
In a 2021 systematic review, dolutegravir-based regimens had virologic suppression rates around 85–90% at 12 months across diverse settings (suppression rate range).
10
In the Rakai trial-linked analyses, protective efficacy of community ART and prevention interventions was estimated at about 26% reduction in incidence in some programmatic comparisons (incidence reduction estimate).
11
In the VESTED study protocol, participants with sustained viral suppression were estimated to have 0.0 linked transmissions as supported by prior PARTNER observations (linked transmission null finding design premise).
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes, the data show that treatment durability and prevention effectiveness are consistently strong, with 95% of people on ART alive and retained at 12 months and viral suppression sustained in 94% over 48 weeks, while trials and observational evidence also report near zero transmission with suppression and large reductions such as a 96% transmission drop in HPTN 052.
More related reading
03 · Category
Market Size7 stats
01
The global HIV diagnostics market was valued at $5.0 billion in 2023 (market valuation).
02
The HIV treatment (antiretrovirals) market was valued at $41.4 billion in 2023 (market valuation).
03
The global HIV PrEP market was projected to reach $2.9 billion by 2030 (forecast).
04
The global HIV self-testing market was expected to grow from about $0.9 billion in 2023 to $1.8 billion by 2030 (forecast growth).
05
The global viral load testing market was projected to exceed $1.8 billion by 2030 (forecast).
06
In 2023, Abbott reported sales of about $7.6 billion for its diagnostics segment (diagnostics revenue relevant to HIV testing ecosystems).
07
The global antiretroviral drug manufacturing market was estimated at $15.2 billion in 2022 (estimated manufacturing market size).
Interpretation
Market Size Interpretation
Under the Market Size angle, HIV is already a large and growing ecosystem with antiretrovirals at $41.4 billion in 2023 while diagnostics and related testing are also expanding, including the global PrEP market forecast to reach $2.9 billion by 2030 and self testing doubling from about $0.9 billion in 2023 to $1.8 billion by 2030.
04 · Category
Technology & Devices2 stats
01
Abbott’s mSample handling platforms increased lab throughput by 30% in a 2020 internal study adopted in infectious disease labs (throughput improvement).
02
In 2022, ACT/ARV procurement volumes for WHO-supported HIV commodity programs were over 120 million units (commodity volume).
Interpretation
Technology & Devices Interpretation
In the Technology & Devices space, lab workflows are getting faster with Abbott’s mSample handling platforms boosting throughput by 30% in 2020 while, alongside this capability, WHO-supported HIV programs reached over 120 million units of ACT and ARV procurement volume in 2022.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Global Hiv Statistics. Gitnux. https://gitnux.org/global-hiv-statistics
MLA
Christopher Morgan. "Global Hiv Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-hiv-statistics.
Chicago
Christopher Morgan. 2026. "Global Hiv Statistics." Gitnux. https://gitnux.org/global-hiv-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)